

May 20, 2021

British Columbia Securities Commission
Alberta Securities Commission
Financial and Consumer Affairs Authority of Saskatchewan
Ontario Securities Commission
Superintendent of Securities, Yukon

Dear Sirs/Mesdames:

Re: Nurosene Health Inc. (formerly, Nurosene Inc.)

We refer to the prospectus of Nurosene Health Inc. (formerly Nurosene Inc.) (the “Company”) dated May 20, 2021 relating to the sale of a minimum of 5,555,555 common shares up to a maximum of 8,888,888 common shares of the Company.

We consent to being named in, and to the use in the above-mentioned prospectus, of our report dated April 16, 2021 to the shareholders of the Company on the following financial statements:

- a. Statements of financial position as at September 30, 2020 and September 30, 2019; and,
- b. Statements of loss and comprehensive loss, changes in shareholders’ equity and cash flows for the year ended September 30, 2020 and the period from May 8, 2019 (Date of Incorporation) to September 30, 2019 and the notes to the financial statements for each of the year/period ended September 30, 2020 and 2019.

We report that we have read the prospectus and all information therein and have no reason to believe that there are any misrepresentations in the information contained therein that are derived from the financial statements upon which we have reported or that are within our knowledge as a result of our audit of such financial statements. We have complied with Canadian generally accepted standards for an auditor’s consent to the use of a report of the auditor included in an offering document, which does not constitute an audit or review of the prospectus as these terms are described in the CPA Canada Handbook – Assurance.

Sincerely,

A handwritten signature in black ink that reads 'MNP LLP' in a stylized, cursive font.

**Chartered Professional Accountants
Licensed Public Accountants**